Opportunity assessment and market attractiveness for one of the top 10 pharmaceutical major

  • Benchmarked therapeutic areas with high clinical and market potential

  • Developed potential market scenarios based on client needs

  • One of the top 10 pharmaceutical majors wanted to determine market attractiveness and assess opportunities for its asset being developed for CLL, MCL and WM
  • Key challenges were:
    • Benchmark therapeutic areas being based on diverse parameters involving clinical, regulatory and market assessment
    • Building a 360-degree view of the market by combining market sizing with adoption share
    • Market attractiveness based on regulatory/NCCN approval, adoption, reimbursement and market access
    • Understanding niche therapeutic areas
  • Competitive analysis:
    • Identified key competitors within each indication and patient population
    • Conducted a detailed comparison of the client’s asset and each asset in the pipeline
    • Scored the client’s asset in terms of clinical attractiveness within each indication
  • Market sizing:
    • Adopted a bottom-up sizing approach – from disease prevalence to the diagnosed and drug-treated population in major markets (the US and EU5)
  • Key differentiator analysis:
    • Generated revenue estimations in each indication based on adoption share
    • Factored in the differences for adoption share and launch timelines and estimated duration of therapies
  • Advised on the attractiveness of the indications among CLL, MCL and WM
  • Created market scenarios based on regulatory approvals, reimbursement and market access
  • Built a dashboard to enable the client to customise results based on assumptions
Thank you for sharing your details

Your file will start downloading automatically

If it does not download within 1 minute,

Share this on

What we have done

Competitor benchmarking and performance gap analysis for a leading European medical device player
What we are proud of

Identified opportunities for expansion and plausible revenue streams

Identified potential geographies and activation levers from competitors

Assessing viability of entering the NSCLC market
What we are proud of

Evaluated unmet needs to identify potential entry points

Conducted a deep-dive study of key assets and key players

Supplier assessment and industry benchmarking for a global top 10 pharmaceutical company
What we are proud of

Optimised vendor-associated costs across geographies

Identified billing arrangements across law firms

Assessment of GCC pharmaceutical market for a global European pharma major
What we are proud of

Analysed potential for entry into the GCC pharmaceutical market

Assessed possible market drivers and barriers to entry